insights_auto
Why is LGND up 2,31%?
Dive Deeperchevron_right
LGND:NASDAQ
Ligand Pharmaceuticals Inc
301,81 US$
arrow_upward
+2,31%(+6,81) 1D
301,81 US$
0,00% (0,00)
bedtimeAfter hours
Closed: 9 ოქტ, 16:00:01 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LGND...
Open
294,79 US$
High
304,78 US$
Low
294,32 US$
Mkt. cap
6,02 მლრდ.
Avg. vol.
247,38 ათ.
Volume
182,27 ათ.
P/E ratio
32,10
52-wk high
326,63 US$
52-wk low
175,89 US$
EPS
9,40 US$
Beta
1,06
Shares outstanding
19,94 მლნ.
No. of employees
47
Open
294,79 US$
High
304,78 US$
Low
294,32 US$
Mkt. cap
6,02 მლრდ.
Avg. vol.
247,38 ათ.
Volume
182,27 ათ.
P/E ratio
32,10
52-wk high
326,63 US$
52-wk low
175,89 US$
EPS
9,40 US$
Beta
1,06
Shares outstanding
19,94 მლნ.
No. of employees
47
News stories
From web sources and news partners
Yahoo Finance
·
1 დღის წინ
Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts
Benzinga
·
2 დღის წინ
Full Transcript: Ligand Pharmaceuticals Q2 2026 Earnings Call
https://www.dars.gov.et/
·
2 კვირის წინ
Ligand Pharmaceuticals (LGND) Edges Higher as Shares Trade Near $287 - ETF AUM Growth
Profile
Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol.
The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments.
Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020. Wikipedia
About Ligand Pharmaceuticals Inc
CEO-
Employees47
Foundedსექ 1987
HeadquartersJupiter, ფლორიდა, ამერიკის შეერთებული შტატები
SectorPharmaceutical industry
Websiteligand.com